Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )
NCT02896985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 98
Last updated 2021-03-09
Summary
This is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (LOR).
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-12-16
- Primary Completion
- 2020-03-11
- Completion
- 2020-03-11
Countries
- Canada
Study Locations
More Related Trials
-
Remission in Subjects With Crohn's Disease, 1 Year Phase
NCT00055497 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
NCT00055367 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03105128 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
NCT05068284 ·Status: TERMINATED ·Phase: PHASE2
-
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
NCT00280956 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
NCT00055523 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy
NCT02793778 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
NCT02891226 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
NCT03668249 ·Status: COMPLETED
-
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
NCT01235689 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
NCT00655135 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
NCT00295165 ·Status: TERMINATED ·Phase: PHASE3
-
Correlation Between RISANKIZUMAB's Trough Levels, Clinical and Biological Remission in Moderate to Severe Crohn's Disease: a Retrospective Multicentric Study
NCT06589895 ·Status: COMPLETED
-
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
NCT00562887 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353 ·Status: RECRUITING ·Phase: PHASE3
-
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
NCT02185014 ·Status: COMPLETED ·Phase: PHASE3
-
Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess
NCT02856763 ·Status: COMPLETED
-
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
NCT00615199 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
NCT02394028 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)
NCT01218360 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Remission in Subjects With Crohn's Disease, Open Label Extension
NCT01070303 ·Status: COMPLETED ·Phase: PHASE3
-
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
NCT05928039 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
NCT00409682 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study
NCT06896305 ·Status: RECRUITING ·Phase: NA